Literature DB >> 18651308

Candida spp. in vitro susceptibility profile to four antifungal agents. Resistance surveillance study in Venezuelan strains.

María Mercedes Panizo1, Vera Reviákina, Maribel Dolande, Sofía Selgrad.   

Abstract

The aim of this study was to determine in vitro susceptibility profiles of Venezuelan strains of Candida spp. to four antifungal agents. One hundred and forty five (145) isolates were recovered during a 1-year period (June 2006 to June 2007) from clinical specimens of patients with severe Candida spp. infections in 15 hospitals. In vitro susceptibilities to amphotericin B, fluconazole, itraconazole and voriconazole were determined by modified Etest. Non Candida albicans Candida spp. were the most frequently isolated yeasts (72.4%) in comparison with C. albicans (27.6%). Candida spp. strains showed MIC ranges between <0.002 and 0.5 mug/ml to amphotericin B. While none were found to be resistant to voriconazole, 5.5% and 27.6% of the test strains were resistant to fluconazole and itraconazole, respectively. C. albicans remains the most susceptible of the yeasts studied to fluconazole and itraconazole (P<0.05) when compared with non C. albicans Candida spp. C. krusei showed the greater cross-resistance to azoles, followed by C. glabrata, C. tropicalis and C. parapsilosis, while C. albicans isolates did not demonstrate this characteristic. It is very important to carry out the correct species identification of clinical yeast isolates because they show up variations in both distribution and susceptibility profiles according to the hospital, patient's underlying disease, clinical specimen analyzed, and the geographical region in which the studies were conducted. The Mycology Department of the INHRR is the national reference center responsible for antifungal resistance surveillance, performing the susceptibility tests with isolates recovered from hospitalized patients in public health centres which do not have mycological diagnosis laboratories.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18651308     DOI: 10.1080/13693780802144339

Source DB:  PubMed          Journal:  Med Mycol        ISSN: 1369-3786            Impact factor:   4.076


  10 in total

1.  Distribution of yeast isolates from invasive infections and their in vitro susceptibility to antifungal agents: evidence from 299 cases in a 3-year (2010 to 2012) surveillance study.

Authors:  Wei Li; Yu-An Hu; Fang-Qiu Li; Li-Ning Shi; Hai-Feng Shao; Mei Huang; Ying Wang; Dan-Dan Han; Hong Liao; Chun-Fang Ma; Guo-Yong Zhang
Journal:  Mycopathologia       Date:  2015-01-15       Impact factor: 2.574

2.  Evaluation of antifungal susceptibility testing with microdilution and Etest methods of Candida blood isolates.

Authors:  Dilek Yesim Metin; Suleyha Hilmioglu-Polat; Pinar Samlioglu; Biray Doganay-Oflazoglu; Ramazan Inci; Emel Tumbay
Journal:  Mycopathologia       Date:  2011-03-20       Impact factor: 2.574

3.  [Identification and susceptibility profile of Candida species isolated from hemocultures in hospitals in ParaguayIdentificação e perfil de sensibilidade de Candida spp. isoladas de hemoculturas em hospitais no Paraguai].

Authors:  Gustavo Aguilar; Patricia Araujo; Graciela Lird; Sonia Insaurralde; Aníbal Kawabata; Edelira Ayala; Juan Irala; Rocío Argüello
Journal:  Rev Panam Salud Publica       Date:  2020-09-23

4.  Examination of potential virulence factors of Candida tropicalis clinical isolates from hospitalized patients.

Authors:  Melyssa Negri; Margarida Martins; Mariana Henriques; Terezinha I E Svidzinski; Joana Azeredo; Rosário Oliveira
Journal:  Mycopathologia       Date:  2009-10-23       Impact factor: 2.574

5.  The in vitro antimicrobial activities of metabolites from lactobacillus strains on Candida species implicated in Candida vaginitis.

Authors:  Adenike A O Ogunshe; Mopelola A Omotoso; Victoria B Bello
Journal:  Malays J Med Sci       Date:  2011-10

6.  Epidemiology of Invasive Fungal Infections in Latin America.

Authors:  Jose Sifuentes-Osornio; Dora E Corzo-León; L Alfredo Ponce-de-León
Journal:  Curr Fungal Infect Rep       Date:  2012-01-05

7.  Antifungal and anti-biofilm activity of the first cryptic antimicrobial peptide from an archaeal protein against Candida spp. clinical isolates.

Authors:  Emanuela Roscetto; Patrizia Contursi; Adriana Vollaro; Salvatore Fusco; Eugenio Notomista; Maria Rosaria Catania
Journal:  Sci Rep       Date:  2018-12-04       Impact factor: 4.379

8.  In Vitro Susceptibility and Trailing Growth Effect of Clinical Isolates of Candida Species to Azole Drugs.

Authors:  Kamiar Zomorodian; Azadeh Bandegani; Hossein Mirhendi; Keyvan Pakshir; Navvab Alinejhad; Ali Poostforoush Fard
Journal:  Jundishapur J Microbiol       Date:  2016-02-20       Impact factor: 0.747

9.  Microdilution in vitro Antifungal Susceptibility Patterns of Candida Species, From Mild Cutaneous to Bloodstream Infections.

Authors:  Elham Rezazadeh; Azar Sabokbar; Maryam Moazeni; Mohammad Sadegh Rezai; Hamid Badali
Journal:  Jundishapur J Microbiol       Date:  2016-07-05       Impact factor: 0.747

10.  Bacteriocin-Like Inhibitory Substances from Probiotics as Therapeutic Agents for Candida Vulvovaginitis.

Authors:  Enas Mamdouh Hefzy; Mahmoud A F Khalil; Amal A Ibrahim Amin; Hossam M Ashour; Yasser Fathy Abdelaliem
Journal:  Antibiotics (Basel)       Date:  2021-03-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.